Stock events for Pulmatrix, Inc. (PULM)
Over the past six months, Pulmatrix's stock price has decreased by 57.26%. Key events include the termination of the merger agreement with Cullgen, financial results showing declining revenues and net losses, and plans to divest its iSPERSE™ technology and clinical programs. Q3 2025 financials reported $0 revenue and a net loss of $0.877 million. Q2 2025 financials also reported zero revenue and reduced R&D expenses. Q1 2025 financials showed zero revenue and a net loss of $1.8 million.
Demand Seasonality affecting Pulmatrix, Inc.’s stock price
Pulmatrix's revenue has historically been volatile and primarily derived from collaboration and licensing agreements. The demand for its technology and pipeline are driven by clinical trial progress, regulatory milestones, partnership agreements, and strategic corporate decisions rather than typical consumer demand seasonality. The company's current focus on divesting assets and pursuing new merger opportunities further indicates that traditional demand seasonality for commercialized products is not a relevant factor at this stage.
Overview of Pulmatrix, Inc.’s business
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapeutic products using its patented iSPERSE™ dry powder technology. Their pipeline includes PUR3100 for acute migraine, PUR1800 for AECOPD, and PUR1900 for allergic bronchopulmonary aspergillosis.
PULM’s Geographic footprint
Pulmatrix, Inc. is headquartered in Framingham, Massachusetts, with a primary focus on the United States for product development and commercialization. Cipla is developing PUR1900 for markets outside the U.S., including India. Pulmatrix transferred its Bedford, Massachusetts R&D facility to MannKind Corporation in May 2024.
PULM Corporate Image Assessment
Pulmatrix's brand reputation has been tied to its strategic corporate developments and financial performance. The proposed merger with Cullgen and its subsequent termination, asset divestment plans, and financial performance have affected its reputation. Positive developments, such as the FDA's acceptance of an IND for PUR3100 and the continued development of PUR1900 by Cipla, contribute positively to its scientific and clinical reputation. The cross-license agreement with MannKind Corporation in May 2024 also positively impacted its reputation.
Ownership
Pulmatrix, Inc. has 19 institutional owners and shareholders holding a total of 361,569 shares as of March 5, 2026. Major institutional owners include Renaissance Technologies Llc, BlackRock, Inc., SBI Securities Co., Ltd., Vanguard Group Inc, and Geode Capital Management, Llc.
